Limits...
Infliximab partially alleviates the bite force reduction in a mouse model of temporomandibular joint pain.

Kim SH, Son CN, Lee HJ, Cho HC, Jung SW, Hur JA, Baek WK, Jung HR, Hong JH - J. Korean Med. Sci. (2015)

Bottom Line: From day 1, a significant reduction in BF was observed in the CFA group, and this reduction in BF was statistically significant compared to that in the control group (P < 0.05).However, the degree of reduction in BF was less remarkable compared to that in the CFA group.The reduction in BF caused by injection of CFA into the TMJ could be partially alleviated by the injection of anti-tumor necrosis factor alpha, infliximab.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea. ; Pain Research Center, School of Medicine, Keimyung University, Daegu, Korea.

ABSTRACT
Temporomandibular joint (TMJ) disorder is clinically important because of its prevalence, chronicity, and therapy-refractoriness of the pain. In this study, we investigated the effect of infliximab in a mouse model of TMJ pain using a specially-engineered transducer for evaluating the changes in bite force (BF). The mice were randomly divided into three groups (7 mice per group): the control group, the complete Freund's adjuvant (CFA) group, and the infliximab group. BF was measured at day 0 (baseline BF). After measuring the baseline BF, CFA or incomplete Freund's adjuvant was injected into both TMJs and then the changes in BF were measured at days 1, 3, 5, 7, 9, and 13 after the TMJ injection. For measuring the BF, we used a custom-built BF transducer. Control, CFA, and infliximab groups showed similar baseline BF at day 0. From day 1, a significant reduction in BF was observed in the CFA group, and this reduction in BF was statistically significant compared to that in the control group (P < 0.05). This reduction in BF was maintained until day 7, and BF started to recover gradually from day 9. In the infliximab group also, the reduction in BF was observed on day 1, and this reduction was maintained until day 7. However, the degree of reduction in BF was less remarkable compared to that in the CFA group. The reduction in BF caused by injection of CFA into the TMJ could be partially alleviated by the injection of anti-tumor necrosis factor alpha, infliximab.

No MeSH data available.


Related in: MedlinePlus

Bite force voltage output wave through the computer monitor (A, B).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4414638&req=5

Figure 2: Bite force voltage output wave through the computer monitor (A, B).

Mentions: Prior to use, the calibration of the BF transducer was performed and checked for linearity by suspending a series of calibration weights ranging from 100 to 500 g from the bite plates. The voltage output from each weight was regressed against the force exerted by calibration weights. Output for each set of calibrations was both linear and reproducible, with correlation coefficients (R2) ranging from 0.9902-0.9998 for each calibration. Mice were placed in a cylindrical plastic tube with an opening at one end for accommodating the mouse head. Placing the mice in a cylindrical tube which permits only head movement is a very stressful condition, and therefore, we spent several minutes to acclimate and calm the mice in a cylindrical tube. When the bite transducer was moved towards the mouse at 0.5-1 cm/sec, a bite was invariably induced. We could confirm the induced bite through the voltage output wave appearing in the monitor. When a proper and maximum bite was induced, the voltage output was recorded as a continuous wave at 500 Hz using Labview 2012 (National Instruments, Austin, TX, USA) (Fig. 2A, B). The peak voltage of each bite was determined and converted into force (Newton, N) based on the regression equation derived from calibration. Each animal was tested 3 times/testing day. The interval between two trials was >2 min. The maximum BF the mice produced per trial was recorded as the actual BF, and then averaged for all trials.


Infliximab partially alleviates the bite force reduction in a mouse model of temporomandibular joint pain.

Kim SH, Son CN, Lee HJ, Cho HC, Jung SW, Hur JA, Baek WK, Jung HR, Hong JH - J. Korean Med. Sci. (2015)

Bite force voltage output wave through the computer monitor (A, B).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4414638&req=5

Figure 2: Bite force voltage output wave through the computer monitor (A, B).
Mentions: Prior to use, the calibration of the BF transducer was performed and checked for linearity by suspending a series of calibration weights ranging from 100 to 500 g from the bite plates. The voltage output from each weight was regressed against the force exerted by calibration weights. Output for each set of calibrations was both linear and reproducible, with correlation coefficients (R2) ranging from 0.9902-0.9998 for each calibration. Mice were placed in a cylindrical plastic tube with an opening at one end for accommodating the mouse head. Placing the mice in a cylindrical tube which permits only head movement is a very stressful condition, and therefore, we spent several minutes to acclimate and calm the mice in a cylindrical tube. When the bite transducer was moved towards the mouse at 0.5-1 cm/sec, a bite was invariably induced. We could confirm the induced bite through the voltage output wave appearing in the monitor. When a proper and maximum bite was induced, the voltage output was recorded as a continuous wave at 500 Hz using Labview 2012 (National Instruments, Austin, TX, USA) (Fig. 2A, B). The peak voltage of each bite was determined and converted into force (Newton, N) based on the regression equation derived from calibration. Each animal was tested 3 times/testing day. The interval between two trials was >2 min. The maximum BF the mice produced per trial was recorded as the actual BF, and then averaged for all trials.

Bottom Line: From day 1, a significant reduction in BF was observed in the CFA group, and this reduction in BF was statistically significant compared to that in the control group (P < 0.05).However, the degree of reduction in BF was less remarkable compared to that in the CFA group.The reduction in BF caused by injection of CFA into the TMJ could be partially alleviated by the injection of anti-tumor necrosis factor alpha, infliximab.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea. ; Pain Research Center, School of Medicine, Keimyung University, Daegu, Korea.

ABSTRACT
Temporomandibular joint (TMJ) disorder is clinically important because of its prevalence, chronicity, and therapy-refractoriness of the pain. In this study, we investigated the effect of infliximab in a mouse model of TMJ pain using a specially-engineered transducer for evaluating the changes in bite force (BF). The mice were randomly divided into three groups (7 mice per group): the control group, the complete Freund's adjuvant (CFA) group, and the infliximab group. BF was measured at day 0 (baseline BF). After measuring the baseline BF, CFA or incomplete Freund's adjuvant was injected into both TMJs and then the changes in BF were measured at days 1, 3, 5, 7, 9, and 13 after the TMJ injection. For measuring the BF, we used a custom-built BF transducer. Control, CFA, and infliximab groups showed similar baseline BF at day 0. From day 1, a significant reduction in BF was observed in the CFA group, and this reduction in BF was statistically significant compared to that in the control group (P < 0.05). This reduction in BF was maintained until day 7, and BF started to recover gradually from day 9. In the infliximab group also, the reduction in BF was observed on day 1, and this reduction was maintained until day 7. However, the degree of reduction in BF was less remarkable compared to that in the CFA group. The reduction in BF caused by injection of CFA into the TMJ could be partially alleviated by the injection of anti-tumor necrosis factor alpha, infliximab.

No MeSH data available.


Related in: MedlinePlus